[Efficacy of newly developed food for special dietary use in the diet of patients with non-alcoholic steatohepatitis].

Autor: Sasunova AN; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation., Morozov SV; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation., Sobolev RV; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation., Isakov VA; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation., Kochetkova AA; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation., Vorobyeva IS; Federal Research Centre of Nutrition, Biotechnology and Foоd Safety, 109240, Moscow, Russian Federation.
Jazyk: ruština
Zdroj: Voprosy pitaniia [Vopr Pitan] 2022; Vol. 91 (2), pp. 31-42. Date of Electronic Publication: 2022 Mar 14.
DOI: 10.33029/0042-8833-2022-91-2-31-42
Abstrakt: Although diet plays a leading role in treatment of non-alcoholic fatty disease (and, in particular, non-alcoholic steatohepatitis), specialized foods for the treatment of these patients have not yet been developed. The aim of the study was to assess efficacy of the food for special dietary use (FSDU) in patients with non-alcoholic steatohepatitis. Material and methods . New FSDU contained (% of the RDAs): protein - 8%; fat - 7% (including ω-3 PUFA - 40%); soluble dietary fiber - 180%; phospholipids - 25%; alpha-lipoic acid - 33%; betaine - 10%; 12 mineral substances - 13-44%; 13 vitamins - 24-140%. The study (NCT04308980) was approved by local ethics committee and enrolled patients with diagnosis of NASH. Subjects were randomized to the following groups: those received iso-calorie diet (according to resting energy expenditures, by indirect calorimetry) alone (ICD) and iso-calorie diet + FSDU (2 portions per day, 14 days) (ICD + FSDU group). Safety was assessed based on clinical and laboratory data. Repeated measurements (baseline vs those on the 15th day of the study) of body composition assessed by bioelectrical impedance analysis, and blood chemistry were compared. Results . The results of complex examination of 20 subjects (12 in ICD + FSDU and 8 in ICD group) served as a source for the study. Initially, groups did not differ by age, sex, and body mass index (BMI). The product was well tolerated. In contrast to ICD group, those in ICD + FSDU group demonstrated greater decrease of weight: BMI initially (BMI0) (M±σ): 38.7±5.4 kg/m 2 vs BMI at the end-point (BMI EOT ) 36.7±5.1 kg/m 2 , p=0.003 in ICD + FSDU group, whereas in the ICD group BMI0=38.9±7.2 vs BMI EOT =38.9±7.3 kg/m 2 , p=0.08. These results were reached predominantly by a decrease of fat mass: body fat weight (BFW 0 ) 50.2±10.7 vs BFW EOT =48.5±10.8 kg, p=0.002 in ICD + FSDU group, whereas BFW 0 =48.9±11.4 vs BFW EOT =47.8±11.6 kg, p=0.07 in ICD group. The activity of alanine and aspartate aminotransferase, gamma-glutamil transpeptidase and alkaline phosphatase decreased in ICD + FSDU group (р=<0.05), whereas in ICD group the difference between initial and control assessment was not significant (р=<0.10). Conclusion . The new FSDU is well tolerated by patients with NASH. In combination with iso-calorie diet, it may increase efficacy of weight loss, predominantly by fat.
Competing Interests: The authors declare no overt and potential conflict of interest related to the publication of this article.
(Copyright© GEOTAR-Media Publishing Group.)
Databáze: MEDLINE
Externí odkaz: